Roquefort Therapeutics (LON:ROQ) has signed binding heads of terms for a reverse takeover of Coiled Therapeutics, securing exclusivity until January 2026 with a US$1m termination fee.
Executive Chairman Stephen West explains how AO-252, Coiled’s first-in-class oncology asset, could reshape Roquefort’s pipeline, transform shareholder value, and set the stage for an AIM relist with an eye on NASDAQ.
Roquefort Therapeutics is a UK-based biotechnology company advancing next-generation cancer therapies. Through its latest transaction with Coiled Therapeutics, it is transitioning from pre-clinical research to a clinical-stage oncology player with ambitions to expand into global markets.
